Barts Health Nhs Trust

Severe COVID-19 infection is linked to accelerated kidney function decline, more pronounced than pneumonia, highlighting the need for kidney function monitoring in hospitalized COVID-19 patients.

The NIHR is investing £72 million to establish 14 new Commercial Research Delivery Centres (CRDCs) in England to enhance commercial clinical research speed and efficiency. These centres will support UK's status as a top research location, decentralize clinical trials to community settings, and ensure research inclusion for all eligible communities. Funded by the VPAG Investment Programme and NIHR, the initiative aims to boost UK's life sciences sector and economic growth.

£100 million public-private investment to set up 20 research hubs across the UK, enhancing access to cutting-edge treatments and clinical trials in community settings, boosting economic growth and research delivery leadership in various medical conditions.

PDS Biotechnology announces a Key Opinion Leader event on Dec 17, 2024, to discuss HPV16-positive HNSCC and the VERSATILE-003 Phase 3 trial of Versamune® HPV + pembrolizumab. Panelists include Dr. Francis Worden and Dr. Kevin Harrington, moderated by Dr. Kirk Shepard.

Nine hospital trusts in England account for 51.1% of patients waiting at least 1.5 years for pre-planned treatment, with University Hospitals Sussex leading at 21.4%. Despite improvements, challenges remain due to high demand and social care issues.

Research in Nature Medicine reveals genetic factors causing type 2 diabetes in South Asians, leading to earlier onset, quicker complications, and weaker medication responses. Key findings include reduced insulin production and unfavorable fat distribution, identifying a high-risk group developing diabetes 8 years earlier at lower BMI. The study emphasizes the need for precision treatments tailored to genetic risk.

Paul Hudson, Sanofi CEO, reflects on carrying the Paralympics torch and the firm's efforts to become a drug discovery powerhouse. He discusses the UK's lagging investment in life sciences, the importance of NHS reimbursement for new medicines, and the potential of AI in healthcare, exemplified by Sanofi's partnership with Barts Health NHS trust.

Perioperative durvalumab plus neoadjuvant chemotherapy followed by radical cystectomy and adjuvant chemotherapy demonstrated significant event-free survival and overall survival benefits in cisplatin-eligible muscle-invasive bladder cancer patients, according to the NIAGARA study presented at the 2024 ESMO Congress.